UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 26, 2014

 

 

Progenics Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware		000-23143		13-3379479
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York				10591
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (914) 789-2800

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 8.01

Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today completed its previously-announced underwritten public offering of 7,608,696 primary shares of common stock at a public offering price of $4.60 per share. Net proceeds to Progenics were approximately $32.6 million after discounts and commissions and estimated expenses. Jefferies LLC acted as sole book-running manager and as representative of the several underwriters named in the underwriting agreement. The offering was made under Progenics’ $150 million shelf registration statement, including a February 21st prospectus supplement.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 26, 2014